Evidence map›Paper›PMID 39562439›Full record

ReviewAdvances in neurobiology2024

Biomarker Methodologies: A NIMH Perspective.

Margaret C Grabb, Linda S Brady

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in neurobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Reliability of short interval cortical inhibition in children with attention deficit hyperactivity disorder.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Margaret C GrabbNational Institutes of Health, National Institute of Mental Health, Rockville, MD, USA. mgrabb@mail.nih.gov.
Linda S BradyNational Institutes of Health, National Institute of Mental Health, Rockville, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biomarkers are critically important in the development of drugs, biologics, medical devices, and psychosocial interventions for psychiatric disorders. As the lead federal agency charged with setting and supporting the national agenda for mental health research, the National Institute of Mental Health (NIMH) funds a broad portfolio of basic, translational, and clinical research focused on identifying, developing, and validating biomarkers for serious mental illnesses and neurodevelopmental conditions. In psychiatric research over the past 10 years, there has been an intensive effort to identify biomarkers as potential tools to improve treatment options for individuals with mental health concerns and increase success in the development of novel interventions. This chapter highlights examples of biomarker technologies that have been utilized to advance understanding of the pathophysiology of psychiatric disorders and the development of novel therapeutics.

Indexed as

BiomarkersMental DisordersNational Institute of Mental Health (U.S.)HumansUnited StatesBiomarkersContext of useDrug development toolsMulticomponent biomarkersNeurotechnologiesPublic-private partnerships

Identifiers

PMID39562439

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.